Education Program
Plasma Cell Disorders, Diseases, Therapies, Lymphoid Malignancies, Technology and Procedures
Seaport Ballroom EFGH
(Manchester Grand Hyatt San Diego)
Description:
Multiple myeloma (MM) is a clinically and biologically highly heterogeneous disease, as the overall survival can vary from more than a decade in patients with standard risk disease treated with intensive chemotherapy to 2-3 years in patients with high-risk features. Current standard of care includes the use of antiCD38 monoclonal antibodies upfront, both in patients eligible for transplant and in transplant non eligible patients, in combination with immunomodulatory agents and/or proteasome inhibitors. Recently, anti BCMA therapies have also been introduced with impressive efficacy results in late lines of treatment, and studies are evaluating their role in earlier phases. This educational session will explore the evidence for best practices for patients with relapsed/refractory MM including a focus on treatment of functional high risk patients, relapse after anti CD38 therapies and relapse after anti-BCMA treatment. Dr. Francesca Gay will discuss the treatment approach for “functional high-risk patients”, typically defined as patients who do not necessarily display baseline high-risk features but show a suboptimal response to induction therapy or relapse early after treatment initiation. She will first review the current available known risk factors to promptly identify these patients, and then focus on the possible management. Dr. Monique Hartley-Brown will focus on the management of relapsed/refractory multiple myeloma post anti-CD38 therapy exposure. She will discuss data for using BCMA targeted therapy options and non-BCMA targeted therapies in 1st and 2nd relapse disease, including cellular therapies in these earlier relapse disease setting. Dr. Adam Cohen will discuss potential options for the patient progressing after a BCMA-targeted therapy, including switching to a different BCMA-targeted therapy, trying a non-BCMA-targeted, T cell- directed therapy, re-exploring a standard myeloma triplet/quadruplet regimen, or trying a novel non-T cell-directed therapy. Finally, he will review patient- and disease-related factors that may help guide decision-making.
Chair:
Francesca Gay, MD, PhD, Division of Hematology 1, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino
Disclosures:
Gay: GlaxoSmithKline: Honoraria, Other: Advisory board; AbbVie: Honoraria, Other: Advisory board; Roche: Other: Advisory board; Oncopeptides: Other: Advisory board; Bristol Myers Squibb/Celgene: Honoraria, Other: Advisory board; Sanofi: Honoraria, Other: Advisory board; Pfizer: Honoraria, Other: Advisory board; Takeda: Honoraria, Other: Advisory board; Janssen: Honoraria, Other: Advisory board; Amgen: Honoraria, Other: Advisory board.
Multiple myeloma (MM) is a clinically and biologically highly heterogeneous disease, as the overall survival can vary from more than a decade in patients with standard risk disease treated with intensive chemotherapy to 2-3 years in patients with high-risk features. Current standard of care includes the use of antiCD38 monoclonal antibodies upfront, both in patients eligible for transplant and in transplant non eligible patients, in combination with immunomodulatory agents and/or proteasome inhibitors. Recently, anti BCMA therapies have also been introduced with impressive efficacy results in late lines of treatment, and studies are evaluating their role in earlier phases. This educational session will explore the evidence for best practices for patients with relapsed/refractory MM including a focus on treatment of functional high risk patients, relapse after anti CD38 therapies and relapse after anti-BCMA treatment. Dr. Francesca Gay will discuss the treatment approach for “functional high-risk patients”, typically defined as patients who do not necessarily display baseline high-risk features but show a suboptimal response to induction therapy or relapse early after treatment initiation. She will first review the current available known risk factors to promptly identify these patients, and then focus on the possible management. Dr. Monique Hartley-Brown will focus on the management of relapsed/refractory multiple myeloma post anti-CD38 therapy exposure. She will discuss data for using BCMA targeted therapy options and non-BCMA targeted therapies in 1st and 2nd relapse disease, including cellular therapies in these earlier relapse disease setting. Dr. Adam Cohen will discuss potential options for the patient progressing after a BCMA-targeted therapy, including switching to a different BCMA-targeted therapy, trying a non-BCMA-targeted, T cell- directed therapy, re-exploring a standard myeloma triplet/quadruplet regimen, or trying a novel non-T cell-directed therapy. Finally, he will review patient- and disease-related factors that may help guide decision-making.
Francesca Gay, MD, PhD
Division of Hematology 1, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
Monique A Hartley-Brown, MD
Medical Oncology, DFCI, Boston, MA
Adam D. Cohen, MD
The Trustees of The University of Pennsylvania, Philadelphia, PA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.